Short interest in Iovance Biotherapeutics (NYSE:IOVA) has seen a 6.67% decrease since the latest report on March 1, 2024. This amounts to 42.98 million shares being sold short, representing 16.64% of all regular shares available for trading. On average, traders would require approximately 7.73 days to cover their short positions.
_____
Short interest is a key indicator of market sentiment towards a stock. An increase in short interest may suggest bearishness, while a decrease could signal bullishness. In comparison to its peers in the medical sector, Iovance Biotherapeutics currently has a short interest of 21.02%. Short interest levels above 10% are considered high and reflect pessimism, while levels below 10% indicate positive sentiment.
_____
Notable institutional investors shorting Iovance Biotherapeutics include Wolverine Trading LLC, Citadel Advisors LLC, and others. A favorable short interest percentage for the company is below 10%, indicating positive investor sentiment. Conversely, a percentage over 20% suggests widespread negativity. As of now, 21.02% of Iovance Biotherapeutics’ floating shares are sold short.
_____
The short interest ratio for IOVA shares currently stands at 4.0, signaling some pessimism about the stock. A ratio above 10 typically indicates strong negativity towards a stock. Short interest data is updated every two weeks and offers valuable insights into investors’ bets on a stock’s potential decline in value.
IOVA Stock Price Drops 8.72% on March 1, 2024: Pre-Market Trading Shows Signs of Reversal
On March 1, 2024, IOVA stock experienced a significant drop in price, closing at $15.91, which was a decrease of $1.52 or 8.72% from the previous market close. Despite this decline, IOVA is still trading near the top of its 52-week range and above its 200-day simple moving average, indicating some level of stability in the stock.
However, there may be some hope for IOVA investors as the stock has shown a slight increase of $0.35 in pre-market trading. This uptick could potentially signal a reversal in the downward trend seen during the previous trading session.
IOVA Stock Performance Analysis: Mixed Results in Net Income and EPS
On March 1, 2024, IOVA stock had a mixed performance based on the available financial data. The company’s net income for the past year was reported at -$444.04 million, showing a decrease of 12.16% compared to the previous year. However, the net income for the fourth quarter was -$116.38 million, which represented a 2.3% increase from the previous quarter. Earnings per share (EPS) for IOVA stock was reported at -$1.89 for the past year, indicating a 24.03% increase from the previous year. The EPS for the fourth quarter was -$0.45, showing no change from the previous quarter. Investors and analysts may view the mixed performance of IOVA stock with caution, as the company’s net income has shown both decreases and increases over the past year and quarter. The positive increase in EPS for the past year may be a promising sign for some investors, but the lack of total revenue data makes it challenging to gauge the company’s overall financial stability. As with any investment, it is important for investors to conduct thorough research and consider all available financial data before making any decisions regarding IOVA stock. Consulting with a financial advisor may also provide valuable insights into the potential risks and rewards associated with investing in this company.
